PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

Eligibility Criteria

• 1. Healthy male and female participants aged 65 ≥ years old
• 2. Prior exposure to THC or cannabis least once in the last 10 years; 1-10 times in the last 20 years; or more than 20 times in their lifetime
• 3. Capable of providing informed consent in English.
• 1. Meeting DSM-5 criteria for psychiatric/substance use disorders (SUD) other than tobacco use disorder, within the last year
• 2. Current use of cannabinoid products, as evidenced by a urine drug screen
• 3. Having a history of treatment for cannabis use disorder
• 4. History of intent or current intent of abstaining from cannabis use
• 5. Clinically significant medical disorders (e.g. liver/kidney dysfunction, immunosuppressing conditions, history or presence of epilepsy, seizures, head trauma with loss of consciousness)
• 6. Medical conditions that increase the risk of respiratory problems (e.g. COPD, asthma, recuring bronchitis, reactive airway disorder)\* (does not apply to the Oral THC Sub-Study)
• 7. History of environmental sensitivities (e.g. bronchospastic allergies, multiple chemical sensitivities) or other airway sensitivities that require the use of an epi pen\*(does not apply to the Oral THC Sub-Study)
• 8. Neurological conditions that may change the response to nociceptive stimuli (e.g., stroke, neuropathy), or that lead to loss of balance, evidenced by a neuro-sensory exam
• 9. Contraindications for exposure to nociceptive stimuli, such as untreated hypertension
• 10. Current regular use of drugs known to affect pain, or that are prominent inducers or inhibitors of CYP2C9, CYP3A4, or UGTA19 (e.g., carbamazepine, valproate, fluvoxamine, and paroxetine)
• 11. Major neurocognitive disorders precluding participation, evidenced by a clinical exam
• 12. Abnormal EKG, arrythmia, vasospastic disease, chronic heart failure, or presence of a pacemaker
• 13. Elevation of liver enzymes (ALT, AST) 2x the normal limit or higher
• 14. Personal or family history of primary psychotic disorders, or mood disorders with psychotic features
• 15. Current suicidal ideation
• 16. Allergy or serious adverse reactions to sesame oil, THC, or cannabis
• 17. Having received any drug as part of a research study within 30 days prior to receiving the study medication in the current study.